Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Massachusetts for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Massachusetts only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Massachusetts (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Babak Jian Seyedahmadi (NPI 1538262761)

Field	Value
Entity Type	Individual
Organization	Babak Jian Seyedahmadi
Address	97 Libbey Industrial Pkwy Ste 100
City	East Weymouth
State	MA
ZIP	02189
Taxonomy	Ophthalmology Physician
NPI Enumerated	September 6, 2006

Payer Source	Total Paid
Medicare	$4.4M
Medicaid	$0

Key Findings

This provider’s Medicare activity is dominated by intravitreal biologic therapy and retinal diagnostics: the top revenue codes are J0178, J2778 and Q5124 (anti–VEGF/retinal injectables and a ranibizumab biosimilar), and imaging and injection procedure codes such as 92134 and 67028 also appear prominently. The procedure mix (multiple high-volume intravitreal injection codes plus high-volume retinal imaging) indicates an operation focused on medical retina care and recurring injection visits rather than primarily surgical retina or general ophthalmology services.

Revenue is highly concentrated in a few drug codes: the precomputed top 3 Medicare codes account for 55.2% of this provider’s total Medicare revenue, with J0178 reporting $948.1K (21.6%), J2778 $828.6K (18.9%), and Q5124 $642.9K (14.7%). This concentration signals that Medicare revenue is largely driven by repeat injectable therapies rather than dispersed E/M or diverse procedural billing.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $4.4M and there is no Medicaid billing on file. For contracting and risk-sharing analyses, this provider should be treated as Medicare-dependent with no measurable Medicaid footprint in the supplied data.

Competitive standing varies by product: the provider ranks highly for biosimilar ranibizumab with Q5124 at #6 of 122 providers nationally (96th percentile; typical, unremarkable volume for this code) and for ranibizumab J2778 at #57 of 1208 (95th percentile; typical, unremarkable volume), indicating above-average use of ranibizumab products. By contrast, J0178 (aflibercept) is #913 of 3204 (71th percentile; typical, unremarkable volume), suggesting aflibercept use is more typical relative to national peers rather than dominant.

Several codes show extreme national concentration that mark this practice as a very high-volume injection and imaging site: 67028 has 5K claims and ranks #7 of 4255 providers nationally (100th percentile; extreme outlier), 92134 has 6.1K claims and ranks #13 of 26868 (100th percentile; extreme outlier), and 92014 has 2.7K claims and ranks #91 of 35415 (100th percentile; extreme outlier). Those extreme-outlier labels, combined with large claim counts, imply unusually high throughput of injection visits and retinal imaging compared with peers.

The drug portfolio includes notable adoption of newer or high-cost agents and unclassified billing: J2781 (pegcetacoplan) appears with 2.5K claims and $300.6K revenue, ranking #20 of 490 (96th percentile; notably above typical national volume for this code), and J3490 (unclassified drugs) contributed $323.5K from 183 claims and ranks #374 of 2838 (87th percentile; typical, unremarkable volume). These items indicate active use of novel therapeutics and occasional use of non–J-code billed pharmacologic agents that materially contribute to revenue.

Tenure and market presence are established: the provider’s NPI was enumerated on 2006-09-06 (~20 years ago), indicating long-standing presence in the market which likely supports the high procedural volumes and repeat-injection patient base observed. This longevity strengthens the interpretation that the observed high volumes reflect sustained clinical operations rather than short-term spikes.

There is some variation across drug adoption and volume tiers that matters for competitive and contracting decisions: J9035 (bevacizumab) shows high relative national rank (#10 of 1852, 100th percentile; extreme outlier) suggesting substantial bevacizumab use, whereas J2777 (faricimab) at 4.6K claims yields $132.2K and ranks #1591 of 2039 (22th percentile; typical, unremarkable volume) indicating lower relative use of that agent. The split across specific injectable agents suggests the practice favors certain therapies (notably ranibizumab biosimilar and ranibizumab) while maintaining significant volume in bevacizumab and pegcetacoplan, which has implications for drug spend, supplier negotiations, and pathway-of-care modeling.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

27 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	1,380	$690	$948.1K
J2778	Injection, ranibizumab, 0.1 mg	4,500	$180	$828.6K
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	4,100	$160	$642.9K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	5,020	$90	$461.4K
J3490	Unclassified drugs	180	$1,770	$323.5K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	2,510	$120	$300.6K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	2,710	$100	$257.6K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	6,070	$30	$194.2K
J2777	Injection, faricimab‑svoa, 0.1 mg	4,560	$30	$132.2K
J9035	Injection, bevacizumab, 10 mg	2,320	$50	$125.3K

Showing 1–10 of 27

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 27 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Massachusetts Distribution

Babak Jian Seyedahmadi — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Massachusetts

Full comparison — all codes billed, vs. state median

27 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	25	90	790	$690	$826.5K
J2777	37	50	7,080	$30	$343.1K
J2778	3	30	560	$180	$200.7K
Q5124	1	10	800	$160	$186K
J2781	1	10	550	$120	$117.4K
67028	1	120	570	$100	$80.7K
J3490	4	20	60	$380	$49.5K
92014	7	1,070	160	$90	$30.1K
67042	10	30	20	$1,170	$25.7K
J9035	1	80	250	$50	$19.7K

Showing 1–10 of 27

Related Providers

Other providers that share a Tax Identification Number (TIN) with Babak Jian Seyedahmadi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The General Hospital Corporation	MA	General Acute Care Hospital	$0	$438M
Community Physicians Of Indiana Inc	IN	Family Medicine Physician	$0	$185M
Massachusetts General Physicians Organization Inc	MA	Dermatology Physician	$0	$60.2M
Boston Emergency Physician Foundation, Inc.	MA	Emergency Medicine Physician	$0	$24.3M
Colorado Permanente Medical Group, P.C.	CO	Internal Medicine Physician	$0	$23.2M
Mohammad Suhail	RI	Internal Medicine Physician	$126.3K	$16M
David Reed	MA	Retina Specialist (Ophthalmology) Physician	$7.7M	$0
Torsten Wiegand	MA	Retina Specialist (Ophthalmology) Physician	$7.6M	$0
Yusef Haj-darwish	MA	Emergency Medicine Physician	$744K	$5M
Andrew Lipman	FL	Medical Oncology Physician	$5.6M	$0

Nearby Providers

Other providers in the same ZIP code as Babak Jian Seyedahmadi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
South Shore Support Services	MA	Home Health Agency	$0	$26.8M
Active Ma, Inc.	MA	Adult Day Care Clinic/Center	$0	$9.3M
Mark Dacey	MA	Ophthalmology Physician	$2.1M	$0
James Stefater	MA	Ophthalmology Physician	$1.6M	$0
Heidi Anderson-dockter	MA	Dermatology Physician	$806.3K	$0
Ramy Rizkalla	MA	Ophthalmology Physician	$627.4K	$1K
Anita Shukla	MA	Ophthalmology Physician	$604.9K	$560
Mary Lisa Mcham	MA	Ophthalmology Physician	$571.6K	$0
Teresa Degiacomo	MA	Dermatology Physician	$537K	$0
Kimberly Hsu	MA	Ophthalmology Physician	$451.8K	$0

Babak Jian Seyedahmadi — Billing Profile & Reimbursement Data

Sign up for Babak Jian Seyedahmadi — Billing Profile & Reimbursement Data policy alerts

Babak Jian Seyedahmadi — Billing Profile & Reimbursement Data

Sign up for Babak Jian Seyedahmadi — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References